NDAINTRAMUSCULARINJECTABLE
Approved
Jun 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
TRELSTAR (triptorelin pamoate) by Verity Pharmaceuticals. Approved for prostate cancer, central precocious puberty, endometriosis. First approved in 2001.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRELSTAR (triptorelin pamoate) is an injectable GnRH agonist administered intramuscularly for the treatment of advanced prostate cancer and endometriosis-related conditions. The drug works by suppressing luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone production in men and estrogen suppression in women. TRELSTAR represents a mature, well-established therapy in the gonadotropin-releasing hormone agonist class with multiple dosing formulations available.
$0.0BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Worked on TRELSTAR at Verity Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.